Hong Kong - Novotech, a leading biotech specialist CRO in the Asia-Pacific region, and virtual research organization (VRO) partner ObvioHealth have been selected as finalists for the Clinical Partnership of the Year Citeline Award by Informa Pharma Intelligence.
ObvioHealth is Novotech’s preferred provider for virtual clinical trials in APAC, while Novotech is ObvioHealth’s preferred CRO in the region for hybrid and virtual trials.
"Our efficient approach to conducting clinical trials is a key driver of our growth in the biotech space, where clients are seeking faster and more cost-efficient solutions," said John Moller, CEO at Novotech.
"Virtual trials offer patients greater access to the important clinical trials conducted across our region,” he added.
“Citeline’s recognition of this partnership with ObvioHealth further demonstrates to biotechs the exceptional access we offer for clinical research in the APAC region.”
Commenting on the partnership, Ivan Jarry, CEO of ObvioHealth said “Asia-Pacific is an area of opportunity for ObvioHealth– not only is it the fastest growing region for clinical trials, but we’re also seeing a growing interest in DCTs, especially from patients in APAC who are increasingly accepting and adopting digital health tools. Our partnership with Novotech provides us with the local expertise often required when conducting studies in APAC where regulatory agencies, language and cultural customs vary by country.”
Judges for the awards include some of the leading figures in biopharma.
See the list here: https://pharmaintelligence.informa.com/events/awards/citeline-awards-2021/judges
According to Pharma Intelligence:
“Our commitment to awards entrants and attendees starts with the selection of independent judges who volunteer their time, experience, and consideration of the hundreds of entries to our various annual global awards.
The judges, invited from all core sectors of the clinical R&D industry, engage in the judging process independently by using their industry knowledge and experience to score entries against the entry criteria. The judges' scores are all combined, giving us the shortlist and winners.”
The Asia-Pacific region is the fastest growing region in the global CRO market, offering access to vast patient populations, quality data and expedited regulatory processes.
Novotech, which specialises in conducting clinical research in Asia-Pacific for biotech companies, has offices across the Asia-Pacific region with local expertise in each market essential to the success of clinical trials in this region.
Novotech has also recently been awarded the ‘2021 Frost & Sullivan Asia-Pacific CRO Company of the Year’. This is the fifth consecutive year that Novotech has been recognized with the prestigious CRO regional award.
About ObvioHealth
ObvioHealth is an end-to-end Virtual Research Organization (VRO) combining virtual site and CRO capabilities to delivers better data to sponsors and an easier clinical trial experience for participants. The company developed and launched one of the first DCT apps, downloadable on smartphones enabling people to participate in clinical trials from the comfort of their homes. In the 4 years since launch, the company has been awarded more than 40 studies from 28 blue chip clients, implemented in 28 countries, in 16 different therapeutic areas. For more information, visit https://www.obviohealth.com.
媒體聯絡人
David James
關於Novotech健康控股
Novotech 是國際公認具有全球執行能力、首屈一指、以亞太地區為中心的生物科技領域受託研究機構 (CRO)。Novotech 是具備實驗室、第 I 期臨床試驗設施、藥物開發諮詢服務、以及美國食品藥物管理局 (FDA) 法規專業知識的臨床 CRO，擁有超過 5,000 個臨床試驗專案的經驗，包含第 I 期到第 IV 期臨床試驗和生體相等性研究。Novotech 主要服務的客戶群是在亞太地區、美國和歐洲進行臨床試驗的生物科技公司。Novotech 在全球擁有超過 3,000 名員工和 34 個辦公室據點。
如需更多資訊，請造訪 https://novotech-cro.com/ct/contact